Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Countries citing papers authored by William A. Creasey
Since
Specialization
Citations
This map shows the geographic impact of William A. Creasey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William A. Creasey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William A. Creasey more than expected).
Fields of papers citing papers by William A. Creasey
This network shows the impact of papers produced by William A. Creasey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William A. Creasey. The network helps show where William A. Creasey may publish in the future.
Co-authorship network of co-authors of William A. Creasey
This figure shows the co-authorship network connecting the top 25 collaborators of William A. Creasey.
A scholar is included among the top collaborators of William A. Creasey based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with William A. Creasey. William A. Creasey is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Creasey, William A., et al.. (1972). Studies of the antineoplastic activity and metabolism of -(N)-heterocyclic carboxaldehyde thiosemicarbazones in dogs and mice.. PubMed. 32(3). 565–72.40 indexed citations
12.
DeConti, Ronald C., Robert Tomchick, J. A. R. Mead, et al.. (1972). Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone.. PubMed. 32(7). 1455–62.99 indexed citations
13.
Creasey, William A., Robert L. Capizzi, & Ronald C. DeConti. (1970). Clinical and biochemical studies of high-dose intermittent therapy of solid tumors with hydroxyurea (NSC-32065).. PubMed. 54(3). 191–4.10 indexed citations
14.
Creasey, William A.. (1969). Exploitable Molecular Mechanisms and Neoplasia.. The Yale Journal of Biology and Medicine. 42(2). 117–118.14 indexed citations
15.
Creasey, William A., Ronald C. DeConti, & Stephen R. Kaplan. (1968). Biochemical studies with 1 beta-D-arabinofuranosylcytosine in human leukemic leukocytes and normal bone marrow cells.. PubMed. 28(6). 1074–81.12 indexed citations
Creasey, William A., et al.. (1963). Clinical and pharmacological studies with 2',3',5'-triacetyl-6-azauridine.. PubMed. 23. 444–53.57 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.